請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69796完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 廖泰慶 | |
| dc.contributor.author | Kai-Chung Cheng | en |
| dc.contributor.author | 鄭凱中 | zh_TW |
| dc.date.accessioned | 2021-06-17T03:28:19Z | - |
| dc.date.available | 2018-04-18 | |
| dc.date.copyright | 2018-04-18 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2018-03-22 | |
| dc.identifier.citation | Aberg, E., Perander, M., Johansen, B., Julien, C., Meloche, S., Keyse, S.M., Seternes, O.M., 2006. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4. The Journal of biological chemistry 281, 35499-35510.
Archer, C.W., Morrison, H., Pitsillides, A.A., 1994. Cellular aspects of the development of diarthrodial joints and articular cartilage. Journal of anatomy 184 ( Pt 3), 447-456. Armand, S., Tomita, H., Heyraud, A., Gey, C., Watanabe, T., Henrissat, B., 1994. Stereochemical course of the hydrolysis reaction catalyzed by chitinases A1 and D from Bacillus circulans WL-12. FEBS letters 343, 177-180. Balkwill, F., Mantovani, A., 2001. Inflammation and cancer: back to Virchow? Lancet 357, 539-545. Bergmann, O.J., Johansen, J.S., Klausen, T.W., Mylin, A.K., Kristensen, J.S., Kjeldsen, E., Johnsen, H.E., 2005. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 11, 8644-8652. Bettini, G., Morini, M., Marconato, L., Marcato, P.S., Zini, E., 2010. Association between environmental dust exposure and lung cancer in dogs. Veterinary journal 186, 364-369. Bhowmick, N.A., Neilson, E.G., Moses, H.L., 2004. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337. Bissell, M.J., Hines, W.C., 2011. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature medicine 17, 320-329. Boudreau, N., Bissell, M.J., 1998. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Current opinion in cell biology 10, 640-646. Boyd, N.F., Guo, H., Martin, L.J., Sun, L., Stone, J., Fishell, E., Jong, R.A., Hislop, G., Chiarelli, A., Minkin, S., Yaffe, M.J., 2007. Mammographic density and the risk and detection of breast cancer. The New England journal of medicine 356, 227-236. Bukowski, J.A., Wartenberg, D., 1997. An alternative approach for investigating the carcinogenicity of indoor air pollution: pets as sentinels of environmental cancer risk. Environmental health perspectives 105, 1312-1319. Carey, T.E., Kimmel, K.A., Schwartz, D.R., Richter, D.E., Baker, S.R., Krause, C.J., 1983. Antibodies to human squamous cell carcinoma. Otolaryngol Head Neck Surg 91, 482-491. Caron, M., Choquet-Kastylevsky, G., Joubert-Caron, R., 2007. Cancer immunomics using autoantibody signatures for biomarker discovery. Molecular & cellular proteomics : MCP 6, 1115-1122. Chanmee, T., Ontong, P., Konno, K., Itano, N., 2014. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6, 1670-1690. Chatterjee, M., Mohapatra, S., Ionan, A., Bawa, G., Ali-Fehmi, R., Wang, X., Nowak, J., Ye, B., Nahhas, F.A., Lu, K., Witkin, S.S., Fishman, D., Munkarah, A., Morris, R., Levin, N.K., Shirley, N.N., Tromp, G., Abrams, J., Draghici, S., Tainsky, M.A., 2006. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer research 66, 1181-1190. Chen, D.S., Mellman, I., 2013. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10. Chetty, C., Lakka, S.S., Bhoopathi, P., Rao, J.S., 2010. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. International journal of cancer. Journal international du cancer 127, 1081-1095. Chin, K., de Solorzano, C.O., Knowles, D., Jones, A., Chou, W., Rodriguez, E.G., Kuo, W.L., Ljung, B.M., Chew, K., Myambo, K., Miranda, M., Krig, S., Garbe, J., Stampfer, M., Yaswen, P., Gray, J.W., Lockett, S.J., 2004. In situ analyses of genome instability in breast cancer. Nature genetics 36, 984-988. Cintin, C., Johansen, J.S., Christensen, I.J., Price, P.A., Sorensen, S., Nielsen, H.J., 2002. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 95, 267-274. Coffman, F.D., 2008. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Critical reviews in clinical laboratory sciences 45, 531-562. Cohen, D., Reif, J.S., Brodey, R.S., Keiser, H., 1974. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer research 34, 2859-2868. Dandekar, R.C., Kingaonkar, A.V., Dhabekar, G.S., 2011. Role of macrophages in malignancy. Ann Maxillofac Surg 1, 150-154. de Groot, J.F., Yung, W.K., 2008. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer journal 14, 279-285. Desjardins, A., Reardon, D.A., Herndon, J.E., 2nd, Marcello, J., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., Bigner, D.D., Friedman, A.H., Friedman, H.S., Vredenburgh, J.J., 2008. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research 14, 7068-7073. Diesinger, I., Bauer, C., Brass, N., Schaefers, H.J., Comtesse, N., Sybrecht, G., Meese, E., 2002. Toward a more complete recognition of immunoreactive antigens in squamous cell lung carcinoma. International journal of cancer. Journal international du cancer 102, 372-378. Disis, M.L., Calenoff, E., McLaughlin, G., Murphy, A.E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R.B., et al., 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer research 54, 16-20. Dupont, J., Tanwar, M.K., Thaler, H.T., Fleisher, M., Kauff, N., Hensley, M.L., Sabbatini, P., Anderson, S., Aghajanian, C., Holland, E.C., Spriggs, D.R., 2004. Early detection and prognosis of ovarian cancer using serum YKL-40. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, 3330-3339. Dvorak, H.F., 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England journal of medicine 315, 1650-1659. Emery, J.D., Shaw, K., Williams, B., Mazza, D., Fallon-Ferguson, J., Varlow, M., Trevena, L.J., 2014. The role of primary care in early detection and follow-up of cancer. Nature reviews. Clinical oncology 11, 38-48. Folkman, J., 2002. Role of angiogenesis in tumor growth and metastasis. Seminars in oncology 29, 15-18. Francescone, R.A., Scully, S., Faibish, M., Taylor, S.L., Oh, D., Moral, L., Yan, W., Bentley, B., Shao, R., 2011. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. The Journal of biological chemistry 286, 15332-15343. Fuchs, S.M., Krajewski, K., Baker, R.W., Miller, V.L., Strahl, B.D., 2011. Influence of combinatorial histone modifications on antibody and effector protein recognition. Current biology : CB 21, 53-58. Gao, S., Brown, J., Wang, H., Feng, X., 2014. The role of glycogen synthase kinase 3-beta in immunity and cell cycle: implications in esophageal cancer. Archivum immunologiae et therapiae experimentalis 62, 131-144. Gingras, D., Beliveau, R., 2010. Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. Biochimica et biophysica acta 1803, 142-150. Gnjatic, S., Wheeler, C., Ebner, M., Ritter, E., Murray, A., Altorki, N.K., Ferrara, C.A., Hepburne-Scott, H., Joyce, S., Koopman, J., McAndrew, M.B., Workman, N., Ritter, G., Fallon, R., Old, L.J., 2009. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. Journal of immunological methods 341, 50-58. Gonzalez, A., Sosenko, I.R., Chandar, J., Hummler, H., Claure, N., Bancalari, E., 1996. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. The Journal of pediatrics 128, 470-478. Gruntzig, K., Graf, R., Hassig, M., Welle, M., Meier, D., Lott, G., Erni, D., Schenker, N.S., Guscetti, F., Boo, G., Axhausen, K., Fabrikant, S., Folkers, G., Pospischil, A., 2015. The Swiss Canine Cancer Registry: a retrospective study on the occurrence of tumours in dogs in Switzerland from 1955 to 2008. J Comp Pathol 152, 161-171. Gudjonsson, T., Ronnov-Jessen, L., Villadsen, R., Rank, F., Bissell, M.J., Petersen, O.W., 2002. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. Journal of cell science 115, 39-50. Hakala, B.E., White, C., Recklies, A.D., 1993. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268, 25803-25810. Hanash, S., 2003. Harnessing immunity for cancer marker discovery. Nature biotechnology 21, 37-38. Harvey, S., Weisman, M., O'Dell, J., Scott, T., Krusemeier, M., Visor, J., Swindlehurst, C., 1998. Chondrex: new marker of joint disease. Clinical chemistry 44, 509-516. Heemskerk, B., Kvistborg, P., Schumacher, T.N., 2013. The cancer antigenome. The EMBO journal 32, 194-203. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., Kohrt, H.E., Horn, L., Lawrence, D.P., Rost, S., Leabman, M., Xiao, Y., Mokatrin, A., Koeppen, H., Hegde, P.S., Mellman, I., Chen, D.S., Hodi, F.S., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567. Hiom, S.C., 2015. Diagnosing cancer earlier: reviewing the evidence for improving cancer survival. British journal of cancer 112 Suppl, S1-5. Hofland, L.J., van der Burg, B., van Eijck, C.H., Sprij, D.M., van Koetsveld, P.M., Lamberts, S.W., 1995. Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: effects of epidermal growth factor and the somatostatin analogue octreotide. International journal of cancer. Journal international du cancer 60, 93-99. Horbinski, C., Wang, G., Wiley, C.A., 2010. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. International journal of clinical and experimental pathology 3, 226-237. Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K.S., Edgar, M.A., Tanwar, M.K., Rao, J.S., Fleisher, M., DeAngelis, L.M., Holland, E.C., 2006. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 5698-5704. Inoue, T., Meyer, T., 2008. Synthetic activation of endogenous PI3K and Rac identifies an AND-gate switch for cell polarization and migration. PloS one 3, e3068. Jaras, K., Anderson, K., 2011. Autoantibodies in cancer: prognostic biomarkers and immune activation. Expert review of proteomics 8, 577-589. Jensen, B.V., Johansen, J.S., Price, P.A., 2003. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 9, 4423-4434. Johansen, J.S., 2006. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Danish medical bulletin 53, 172-209. Johansen, J.S., Christensen, I.J., Riisbro, R., Greenall, M., Han, C., Price, P.A., Smith, K., Brunner, N., Harris, A.L., 2003. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast cancer research and treatment 80, 15-21. Johansen, J.S., Christoffersen, P., Moller, S., Price, P.A., Henriksen, J.H., Garbarsch, C., Bendtsen, F., 2000. Serum YKL-40 is increased in patients with hepatic fibrosis. Journal of hepatology 32, 911-920. Johansen, J.S., Jensen, B.V., Roslind, A., Nielsen, D., Price, P.A., 2006. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15, 194-202. Johansen, J.S., Schultz, N.A., Jensen, B.V., 2009. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 5, 1065-1082. Johansen, J.S., Williamson, M.K., Rice, J.S., Price, P.A., 1992. Identification of proteins secreted by human osteoblastic cells in culture. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 7, 501-512. Joyce, J.A., Pollard, J.W., 2009. Microenvironmental regulation of metastasis. Nature reviews. Cancer 9, 239-252. Junker, N., Johansen, J.S., Andersen, C.B., Kristjansen, P.E., 2005. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung cancer 48, 223-231. Kalluri, R., Zeisberg, M., 2006. Fibroblasts in cancer. Nature reviews. Cancer 6, 392-401. Kawada, M., Seno, H., Kanda, K., Nakanishi, Y., Akitake, R., Komekado, H., Kawada, K., Sakai, Y., Mizoguchi, E., Chiba, T., 2012. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31, 3111-3123. Kushner, R.F., Craig, R.M., 1982. Intense nutritional support in inflammatory bowel disease: a review. Journal of clinical gastroenterology 4, 511-520. Lau, S.H., Sham, J.S., Xie, D., Tzang, C.H., Tang, D., Ma, N., Hu, L., Wang, Y., Wen, J.M., Xiao, G., Zhang, W.M., Lau, G.K., Yang, M., Guan, X.Y., 2006. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25, 1242-1250. Li, H.F., Kim, J.S., Waldman, T., 2009. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4, 43. Ling, H., Recklies, A.D., 2004. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. The Biochemical journal 380, 651-659. Linnemann, C., van Buuren, M.M., Bies, L., Verdegaal, E.M., Schotte, R., Calis, J.J., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D.E., Visser, M., Stratton, M.R., Haanen, J.B., Spits, H., van der Burg, S.H., Schumacher, T.N., 2015. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nature medicine 21, 81-85. Liu, T., Wang, X., Karsdal, M.A., Leeming, D.J., Genovese, F., 2012. Molecular serum markers of liver fibrosis. Biomarker insights 7, 105-117. Maher, J.J., Bissell, D.M., 1993. Cell-matrix interactions in liver. Seminars in cell biology 4, 189-201. Malinda, K.M., Ponce, L., Kleinman, H.K., Shackelton, L.M., Millis, A.J., 1999. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Experimental cell research 250, 168-173. Marconato, L., Leo, C., Girelli, R., Salvi, S., Abramo, F., Bettini, G., Comazzi, S., Nardi, P., Albanese, F., Zini, E., 2009. Association between waste management and cancer in companion animals. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 23, 564-569. Markert, J.M., Parker, J.N., Gillespie, G.Y., Whitley, R.J., 2001. Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes : the journal of the IHMF 8, 17-22. Martic-Kehl, M.I., Schibli, R., Schubiger, P.A., 2012. Can animal data predict human outcome? Problems and pitfalls of translational animal research. European journal of nuclear medicine and molecular imaging 39, 1492-1496. Merlo, D.F., Rossi, L., Pellegrino, C., Ceppi, M., Cardellino, U., Capurro, C., Ratto, A., Sambucco, P.L., Sestito, V., Tanara, G., Bocchini, V., 2008. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 22, 976-984. Michelsen, A.E., Rathcke, C.N., Skjelland, M., Holm, S., Ranheim, T., Krohg-Sorensen, K., Klingvall, M.F., Brosstad, F., Oie, E., Vestergaard, H., Aukrust, P., Halvorsen, B., 2010. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 211, 589-595. Millis, A.J., Hoyle, M., Mann, D.M., Brennan, M.J., 1985. Incorporation of cellular and plasma fibronectins into smooth muscle cell extracellular matrix in vitro. Proceedings of the National Academy of Sciences of the United States of America 82, 2746-2750. Mitsuhashi, A., Matsui, H., Usui, H., Nagai, Y., Tate, S., Unno, Y., Hirashiki, K., Seki, K., Shozu, M., 2009. Serum YKL-40 as a marker for cervical adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 20, 71-77. Mohanty, A.K., Singh, G., Paramasivam, M., Saravanan, K., Jabeen, T., Sharma, S., Yadav, S., Kaur, P., Kumar, P., Srinivasan, A., Singh, T.P., 2003. Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution. The Journal of biological chemistry 278, 14451-14460. Motz, G.T., Coukos, G., 2013. Deciphering and reversing tumor immune suppression. Immunity 39, 61-73. Mueller, M.M., Fusenig, N.E., 2004. Friends or foes - bipolar effects of the tumour stroma in cancer. Nature reviews. Cancer 4, 839-849. Nagle, R.B., Cress, A.E., 2011. Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis. Prostate cancer 2011, 249290. Neal, R.D., Tharmanathan, P., France, B., Din, N.U., Cotton, S., Fallon-Ferguson, J., Hamilton, W., Hendry, A., Hendry, M., Lewis, R., Macleod, U., Mitchell, E.D., Pickett, M., Rai, T., Shaw, K., Stuart, N., Torring, M.L., Wilkinson, C., Williams, B., Williams, N., Emery, J., 2015. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. British journal of cancer 112 Suppl, S92-S107. Nigro, J.M., Misra, A., Zhang, L., Smirnov, I., Colman, H., Griffin, C., Ozburn, N., Chen, M., Pan, E., Koul, D., Yung, W.K., Feuerstein, B.G., Aldape, K.D., 2005. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer research 65, 1678-1686. Pelloski, C.E., Lin, E., Zhang, L., Yung, W.K., Colman, H., Liu, J.L., Woo, S.Y., Heimberger, A.B., Suki, D., Prados, M., Chang, S., Barker, F.G., 3rd, Fuller, G.N., Aldape, K.D., 2006. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 3935-3941. Pelloski, C.E., Mahajan, A., Maor, M., Chang, E.L., Woo, S., Gilbert, M., Colman, H., Yang, H., Ledoux, A., Blair, H., Passe, S., Jenkins, R.B., Aldape, K.D., 2005. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 11, 3326-3334. Pinho, S.S., Carvalho, S., Cabral, J., Reis, C.A., Gartner, F., 2012. Canine tumors: a spontaneous animal model of human carcinogenesis. Translational research : the journal of laboratory and clinical medicine 159, 165-172. Porrello, A., Cardelli, P., Spugnini, E.P., 2006. Oncology of companion animals as a model for humans. an overview of tumor histotypes. Journal of experimental & clinical cancer research : CR 25, 97-105. Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H.A., Petrylak, D.P., Teng, S.L., Shen, X., Boyd, Z., Hegde, P.S., Chen, D.S., Vogelzang, N.J., 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562. Predina, J., Eruslanov, E., Judy, B., Kapoor, V., Cheng, G., Wang, L.C., Sun, J., Moon, E.K., Fridlender, Z.G., Albelda, S., Singhal, S., 2013. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proceedings of the National Academy of Sciences of the United States of America 110, E415-424. Qian, B.Z., Pollard, J.W., 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51. Qureshi, A.M., Hannigan, A., Campbell, D., Nixon, C., Wilson, J.B., 2011. Chitinase-like proteins are autoantigens in a model of inflammation-promoted incipient neoplasia. Genes & cancer 2, 74-87. Rütgen, B.C., Hammer, S.E., Gerner, W., Christian, M., de Arespacochaga, A.G., Willmann, M., Kleiter, M., Schwendenwein, I., Saalmuller, A., 2010. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res 34, 932-938. Ranieri, G., Gadaleta, C.D., Patruno, R., Zizzo, N., Daidone, M.G., Hansson, M.G., Paradiso, A., Ribatti, D., 2013. A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Critical reviews in oncology/hematology 88, 187-197. Recklies, A.D., White, C., Ling, H., 2002. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. The Biochemical journal 365, 119-126. Rehli, M., Krause, S.W., Andreesen, R., 1997. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43, 221-225. Rejman, J.J., Hurley, W.L., 1988. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochemical and biophysical research communications 150, 329-334. Renkema, G.H., Boot, R.G., Au, F.L., Donker-Koopman, W.E., Strijland, A., Muijsers, A.O., Hrebicek, M., Aerts, J.M., 1998. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. European journal of biochemistry / FEBS 251, 504-509. Richards, M.A., 2009a. The National Awareness and Early Diagnosis Initiative in England: assembling the evidence. British journal of cancer 101 Suppl 2, S1-4. Richards, M.A., 2009b. The size of the prize for earlier diagnosis of cancer in England. British journal of cancer 101 Suppl 2, S125-129. Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., Samuels, Y., Rosenberg, S.A., 2013. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature medicine 19, 747-752. Rubin, G., Walter, F., Emery, J., Neal, R., Hamilton, W., Wardle, J., 2014. Research into practice: prompt diagnosis of cancer in primary care. The British journal of general practice : the journal of the Royal College of General Practitioners 64, 428-430. Ruoslahti, E., 2002. Specialization of tumour vasculature. Nature reviews. Cancer 2, 83-90. Salamon, J., Hoffmann, T., Elies, E., Peldschus, K., Johansen, J.S., Luers, G., Schumacher, U., Wicklein, D., 2014. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PloS one 9, e95822. Scanlan, M.J., Chen, Y.T., Williamson, B., Gure, A.O., Stockert, E., Gordan, J.D., Tureci, O., Sahin, U., Pfreundschuh, M., Old, L.J., 1998. Characterization of human colon cancer antigens recognized by autologous antibodies. International journal of cancer. Journal international du cancer 76, 652-658. Schultz, N.A., Johansen, J.S., 2010. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2, 1453-1491. Schumacher, T.N., Kesmir, C., van Buuren, M.M., 2015. Biomarkers in cancer immunotherapy. Cancer cell 27, 12-14. Shackelton, L.M., Mann, D.M., Millis, A.J., 1995. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. The Journal of biological chemistry 270, 13076-13083. Shanmugam, I., Abbas, M., Ayoub, F., Mirabal, S., Bsaili, M., Caulder, E.K., Weinstock, D.M., Tomkinson, A.E., Hromas, R., Shaheen, M., 2014. Ubiquitin-specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination. The Journal of biological chemistry 289, 22739-22748. Shao, R., Hamel, K., Petersen, L., Cao, Q.J., Arenas, R.B., Bigelow, C., Bentley, B., Yan, W., 2009. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28, 4456-4468. Sharif, M., Granell, R., Johansen, J., Clarke, S., Elson, C., Kirwan, J.R., 2006. Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee. Rheumatology 45, 522-526. Sickles, E.A., 2007. Wolfe mammographic parenchymal patterns and breast cancer risk. AJR. American journal of roentgenology 188, 301-303. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., Hollmann, T.J., Bruggeman, C., Kannan, K., Li, Y., Elipenahli, C., Liu, C., Harbison, C.T., Wang, L., Ribas, A., Wolchok, J.D., Chan, T.A., 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine 371, 2189-2199. Swetha, G., Chandra, V., Phadnis, S., Bhonde, R., 2011. Glomerular parietal epithelial cells of adult murine kidney undergo EMT to generate cells with traits of renal progenitors. Journal of cellular and molecular medicine 15, 396-413. Tarpgaard, L.S., Guren, T.K., Glimelius, B., Christensen, I.J., Pfeiffer, P., Kure, E.H., Sorbye, H., Ikdahl, T., Yilmaz, M., Johansen, J.S., Tveit, K.M., 2014. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. PLoS One 9, e87746. Teravainen, T.P., Myllymaki, S.M., Friedrichs, J., Strohmeyer, N., Moyano, J.V., Wu, C., Matlin, K.S., Muller, D.J., Manninen, A., 2013. alphaV-integrins are required for mechanotransduction in MDCK epithelial cells. PloS one 8, e71485. Thamm, D., Dow, S., 2009. How companion animals contribute to the fight against cancer in humans. Veterinaria italiana 45, 111-120. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A.N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A.J., Grogan, T.R., Mateus, C., Tomasic, G., Glaspy, J.A., Emerson, R.O., Robins, H., Pierce, R.H., Elashoff, D.A., Robert, C., Ribas, A., 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571. Umeki, S., Ema, Y., Suzuki, R., Kubo, M., Hayashi, T., Okamura, Y., Yamazaki, J., Tsujimoto, H., Tani, K., Hiraoka, H., Okuda, M., Mizuno, T., 2013. Establishment of five canine lymphoma cell lines and tumor formation in a xenotransplantation model. The Journal of veterinary medical science / the Japanese Society of Veterinary Science 75, 467-474. van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L.J., Behjati, S., Hilkmann, H., El Atmioui, D., Nieuwland, M., Stratton, M.R., Kerkhoven, R.M., Kesmir, C., Haanen, J.B., Kvistborg, P., Schumacher, T.N., 2013. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, e439-442. Volck, B., Price, P.A., Johansen, J.S., Sorensen, O., Benfield, T.L., Nielsen, H.J., Calafat, J., Borregaard, N., 1998. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proceedings of the Association of American Physicians 110, 351-360. Wang, L., Qian, J., Lu, Y., Li, H., Bao, H., He, D., Liu, Z., Zheng, Y., He, J., Li, Y., Neelapu, S., Yang, J., Kwak, L.W., Yi, Q., Cai, Z., 2013. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98, 1458-1466. Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J.E., Pienta, K.J., Sanda, M.G., Kantoff, P.W., Rubin, M.A., Wei, J.T., Ghosh, D., Chinnaiyan, A.M., 2005. Autoantibody signatures in prostate cancer. The New England journal of medicine 353, 1224-1235. Wolfe, J.N., 1976. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37, 2486-2492. Xing, Z., Gauldie, J., Cox, G., Baumann, H., Jordana, M., Lei, X.F., Achong, M.K., 1998. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. The Journal of clinical investigation 101, 311-320. Yamada, K.M., 1983. Cell surface interactions with extracellular materials. Annual review of biochemistry 52, 761-799. Zhang, Z., Neiva, K.G., Lingen, M.W., Ellis, L.M., Nor, J.E., 2010. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell death and differentiation 17, 499-512. Zhao, Z., Sun, Y., Yang, S., Cui, Q., Li, Z., 2015. FAK activity is required for HGF to suppress TGF-beta1-induced cellular proliferation. In vitro cellular & developmental biology. Animal. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69796 | - |
| dc.description.abstract | 近年來，癌症已成為國內外犬隻的第一大死因，但目前大多數犬癌症的治療仍以傳統的手術切除、化學療法及放射療法為主，療效大多不好；與人類癌症相似的是，早期的診斷能讓癌症患犬得到較好的療效及復原狀況，因此，現階段我們希望找到一個能用於犬癌症早期診斷與治療的生物標記（biomarker）。YKL-40為一種分泌型之醣蛋白，因其結構類似幾丁酶，具有與幾丁質結合之能力而有別名CHI3L1（chitinase-3-like-1），但其酵素活性區域之谷氨酸（glutamic acid）被白胺酸（leucine）所取代，因此不具幾丁酶之活性。而在YKL-40與癌症相關研究中，一般認為血清含有高量YKL-40可能與癌細胞的轉移及病人較短的存活時間有關；除此之外，許多證據顯示YKL-40可能是一種自體抗原，與多種發炎性疾病及發炎所引起的腫瘤有關。然而目前YKL-40的研究都以人類和實驗鼠為主，還沒有犬YKL-40的相關研究，因此，本研究擬純化重組的犬YKL-40及製備抗犬YKL-40之單株抗體，並將其應用於犬癌症醫學之研究。首先，將純化後之犬YKL-40重組蛋白作為免疫抗原，以融合瘤技術製備並經由酵素免疫分析法(ELISA)、免疫墨點法(immunoblot)、免疫螢光染色(immunofluorescence)和免疫組織化學染色(immunohistochemistry)分析後得到專一性的單株抗體，接著以ELISA技術來檢測健康犬與癌症犬血清中的YKL-40和自體抗體(YKL-40 autoantibody, YAA)，並以統計方法分析兩者與犬癌症發展之間的相關性。最後經由生物功能試驗如細胞增生試驗（proliferation）、移行試驗（migration）、侵入能力試驗（invasion）以及管腺生成試驗（tubulogenesis）等來評估犬YKL-40對於癌症細胞的生理功能以及單株抗體的中和效力。由實驗結果得知，犬YKL-40重組蛋白能促進犬淋巴癌細胞的移行，犬腎上皮細胞的增生和管腺生成，而本研究中製備的單株抗體19C12M2則能抑制YKL-40促進的管腺生成。另外，由血清學的檢測和統計分析得知，腫瘤患犬的血清YAA低於健康犬，而YKL-40則高於健康犬；此外，血清YKL-40含量較高的患犬，會有較高的腫瘤復發率及轉移率，一年存活率也顯著較低。綜合以上分析結果，單株抗體19C12M2能阻斷犬YKL-40所促進的管腺生成，血清中高量的YKL-40可能可作為犬癌症預後不良的評估指標。 | zh_TW |
| dc.description.abstract | Cancer is now the number one killer of canine in worldwide. While canine cancer can be treated with surgery, chemotherapy, radiation, and immunotherapy, the prognosis is generally poor. Similar to human cancer, early detection of cancer is most critical for successful treatment and recovery. Therefore, it is urgent to find a biomarker for diagnosis and treatment in early stages of canine cancer. YKL-40 protein, also known as CHI3L1 (chitinase-3-like-1), is a glycoprotein with chitin-binding affinity and lacks chitinase activity due to mutations within the active site. It is considered that high serum level of YKL-40 is correlated with metastasis and poor survival in a variety of human cancer. In addition, YKL-40 may serve as an autoantigen which mediates multiple inflammatory diseases and cancers. However, the role of YKL-40 in dog is still under evaluation. The aim of this study is to develop and characterize monoclonal antibody (mAb) against canine YKL-40 for canine cancer research. Purified recombinant canine YKL-40 (rcYKL-40) was used to develop mouse mAb by hybridoma technology. An ELISA method was then established to detect serum YKL-40 and its autoantibody (YAA) in dogs. Afterward, the bio function of canine YKL-40 were investigated by cell proliferation, migration, invasion assay. Our data show that rcYKL-40 promotes cell migration of canine lymphoma cells, CLC and CLBL-1; mAb 19C12M2 might have potential to block YKL-40 associate cell migration. We also found that patients with higher serum YKL-40 present poor prognosis and worse one-year survival. In conclusion, mAbs we developed could be a useful tool in canine YKL-40 detection, and serum level of YKL-40 might be an independent prognostic factor for canine cancers. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T03:28:19Z (GMT). No. of bitstreams: 1 ntu-104-R02629013-1.pdf: 2632886 bytes, checksum: 1a754612ecb577d67995a71d5128e705 (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | Contents
中文摘要.....................................................................................................................................I Abstract .................................................................................................................................... II Contents...................................................................................................................................IV Chapter 1. Background and Literatures Review................................................................... 1 1.1 Cancer progression and surrounding microenvironment ........................................... 1 1.2 Immunological diagnosis and therapy in cancer ........................................................ 4 1.2.1 The cancer-immunity cycle ................................................................................ 4 1.2.2 Early diagnosis in cancer associated with well outcomes.................................. 6 1.2.3 Biomarkers in cancer immunotherapy ............................................................... 7 1.2.4 Serologic autoantibodies as diagnostic cancer biomarkers ................................ 9 1.3 YKL-40 .................................................................................................................... 11 1.3.1 Expressions and regulations of YKL-40 gene in cancer cell ........................... 12 1.3.2 The relationship between YKL-40 and diseases .............................................. 13 1.3.2.1 YKL-40 in autoimmune disease............................................................................... 13 1.3.2.2 YKL-40 in cancer..................................................................................................... 14 1.4 Cancer in Dog........................................................................................................... 15 1.4.1 Distribution of the Most Common Diagnoses.................................................. 16 1.4.2 Malignancy of the Most Common tumor Diagnoses ....................................... 17 1.4.3 Several factors that increasing canine tumor incidence rate ............................ 17 1.5 Conclusion................................................................................................................ 18 Chapter 2. Introduction ......................................................................................................... 19 Chapter 3. Materials and Methods ....................................................................................... 22 3.1 Cell cultures.............................................................................................................. 22 3.2 Healthy and cancer dogs plasma .............................................................................. 23 3.3 Anti-canine YKL-40 monoclonal antibodies ........................................................... 23 3.3.1 Expression and purification of recombinant canine YKL-40 protein .............. 24 3.3.2 Immune program.............................................................................................. 24 3.3.3 Hybridoma technology..................................................................................... 25 3.3.3.1 Mouse myeloma cell culture .................................................................................... 25 3.3.3.2 Fusion ....................................................................................................................... 25 3.3.4 Indirect enzyme-linked immunosorbent assay (iELISA)................................. 27 3.3.5 Limiting dilution .............................................................................................. 27 3.4 Western blotting analysis.......................................................................................... 28 3.5 Immunofluorescence assay ...................................................................................... 29 3.6 Immunocytochemistry assay.................................................................................... 29 3.7 Establishment of YKL-40 autoantibody ELISA ...................................................... 30 3.8 Serum/plasma YKL-40 detection by ELISA............................................................ 31 3.9 Proliferation assay.................................................................................................... 31 3.10 Invasion assay .......................................................................................................... 32 3.11 Transwell migration assay........................................................................................ 32 3.12 Tubulogenesis assay................................................................................................. 33 3.13 Statistical analysis .................................................................................................... 33 Chapter 4. Results .................................................................................................................. 34 4.1 Preparation of canine YKL-40 monoclonal antibody .............................................. 34 4.1.1 Expression and purification of recombinant canine YKL-40 protein .............. 34 4.1.2 Titers of mice serum detected by ELISA......................................................... 34 4.1.3 Obtained parental hybridomas from HAT selection......................................... 34 4.1.4 Monoclonal hybridomas screened by ELISA and Western blot....................... 35 4.2 Characteristics of YKL-40 mAbs by IFA and ICC analysis..................................... 36 4.3 Canine YKL-40 autoantibody detection by Western blot ........................................ 37 4.4 Establishment of canine YKL-40 autoantibody ELISA........................................... 37 4.5 The S/C value of serum YKL-40 autoantibody decrease cancer development........ 38 4.6 High level of serum YKL-40 present a poor prognosis in cancer dogs ................... 38 4.7 The biological function of canine YKL-40 protein were evaluated by proliferation, invasion, and transwell migration assay. .............................................................................. 41 4.7.1 Proliferation assay............................................................................................ 41 4.7.2 Transwell migration assay................................................................................ 41 4.7.3 Invasion assay .................................................................................................. 42 4.7.4 Tubulogenesis assay......................................................................................... 42 Chapter 5. Discussion............................................................................................................. 44 Tables....................................................................................................................................... 53 Table 1. The primers used for PCR of canine YKL-40 ........................................................ 53 Table 2. The program of mice immunization ....................................................................... 54 Table 3. Parental hybridomas from HAT selection .............................................................. 55 Table 4. mAbs binding activity screened by ELISA, Western blot and IFA........................ 56 Table 5. Demographic of cancer dog cases recruited from NTUVH. .................................. 57 Table 6. Blood level of YKL-40 and autoantibody in cancer dogs ...................................... 58 Table 7. Patients’ characterizations between high and low serum level of YKL-40............ 59 Figures ..................................................................................................................................... 60 Figure A. Cancer immunity cycle ........................................................................................ 60 Figure B. The most prevalent diagnoses over time (1955-2008). ........................................ 61 Figure 1. Schematic diagram of construction of prcYKL-40............................................... 62 Figure 2. Schedule of mouse immunization......................................................................... 63 Figure 3. The generation of hybridoma for monoclonal antibody production. .................... 64 Figure 4. Diagrams of ELISA protocols............................................................................... 65 Figure 5. Purification of recombinant canine YKL-40 protein (46.7 kDa).......................... 66 Figure 6. Mice serum ELISA after immunizations. ............................................................. 67 Figure 7. Hybridoma cells growth in culture plate............................................................... 68 Figure 8. Characterization of YKL-40 mAbs....................................................................... 69 Figure 9. Characteristics of YKL-40 mAbs were analyzed by IFA. .................................... 71 Figure 10. Characteristics of YKL-40 mAbs were analyzed by ICC. .................................. 72 Figure 11. YKL-40 may not be expressed in canine melanoma cell lines. .......................... 73 Figure 12. Western blot analysis of YKL-40 autoantibody in dog serum............................ 74 Figure 13. Detection of serum/plasma YKL-40 autoantibody by ELISA............................ 75 Figure 14. Detection of serum/plasma YKL-40 autoantibody by ELISA............................ 76 Figure 15. Serum/plasma YKL-40 of healthy and cancer dogs. .......................................... 77 Figure 16. Kaplan–Meier survival estimates for cancer dogs according to high and low serum levels of YKL-40. ...................................................................................................... 78 Figure 17. The relationship between YKL-40 and its autoantibody is not proportional...... 79 Figure 18. Effect of recombinant canine YKL-40 on MDCK and canine cancer cells proliferation assay................................................................................................................. 81 Figure 19. Effects of recombinant canine YKL-40 protein on cell migration and invasion assay. ……………………………………………………………………………………...82 Figure 20. Effects of recombinant canine YKL-40 protein on MDCK tubulogenesis assay. ……………………………………………………………………………………...84 References ............................................................................................................................... 85 | |
| dc.language.iso | en | |
| dc.title | 製備應用於犬癌症研究的犬YKL-40 單株抗體 | zh_TW |
| dc.title | Development and Characterization of Canine YKL-40
Monoclonal Antibody for Canine Cancer Research | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 郭村勇,李繼忠,施能耀,王愈善,林辰栖 | |
| dc.subject.keyword | YKL-40,單株抗體,中和抗體,犬癌症,tubulogenesis, | zh_TW |
| dc.subject.keyword | YKL-40,chitinase-3-like-1,CHI3L1,monoclonal antibody,autoantibody,tubulogenesis,canine cancer,ELISA,neutralizing antibody, | en |
| dc.relation.page | 94 | |
| dc.identifier.doi | 10.6342/NTU201800691 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2018-03-23 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
| 顯示於系所單位： | 獸醫學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf 目前未授權公開取用 | 2.57 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。